BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (“Butterfly”, “the Company”) (NYSE: BFLY), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, today published a case study highlighting the positive impact of University of Rochester Medical Center’s (URMC) transformative, system-wide deployment of Butterfly’s point-of-care ultrasound (POCUS) devices and enterprise ultrasound platform, Compass™. The results are backed by an academic paper published yesterday, September 16, 2024, in the Journal of Clinical Imaging Science.
In early 2021, URMC partnered with Butterfly to launch an enterprise-wide ultrasound program designed to improve access to imaging, enhance clinical workflows, and drive value for both patients and providers. To date, URMC has deployed 862 Butterfly devices across 64 academic departments and clinical programs, integrated with Butterfly’s Compass™ workflow software. URMC plans to scale the program to 2,500 devices by 2026. This innovative implementation has resulted in a 116% increase in ultrasound charge capture across the health system.
Since 2022, nearly 50,000 scanning sessions have been completed, generating over 175,000 images and 15,524 finalized reports. This growth has fueled a 74% increase in scanning sessions in 2023, a 147% rise in studies uploaded from Butterfly devices and a 1,782% jump in images uploaded from non-Butterfly devices. These achievements have contributed to earlier diagnoses, such as detecting cholecystitis, abscesses and bladder masses, significantly improving patient outcomes while reducing emergency visits.
“Our phased deployment of Butterfly devices and Compass software has yielded impressive clinical and administrative results at URMC to date. URMC is proud to be at the forefront of the wide-scale deployment of innovative point-of-care ultrasound technology, and we believe it shows promise as the right care model for the medical community at large,” commented Michael F. Rotondo, MD, Chief Executive Officer of the University of Rochester Medical Faculty Group, Senior Vice President of URMC.
“I’m inspired by Dr. Rotondo’s visionary leadership in driving the system-wide deployment of point-of-care ultrasound across URMC. Patients are receiving care earlier, doctors are empowered to make a greater impact, and care is becoming more efficient – proving a compelling return on investment,” said Joseph DeVivo, president, CEO, and board chairman of Butterfly Network. “Health system leaders are recognizing the power of POCUS as a comprehensive solution. Thousands of studies confirm early diagnoses across venues annually, yet many go unrecorded and unreimbursed, resulting in millions of dollars in unbilled ultrasound scans. Individual providers are already onboard; tens of thousands have purchased their own Butterfly devices knowing they improve patient care. Now it’s time for health system C-suites to work with those doctors to build an enterprise-wide POCUS program. This means committing to education, deploying Butterfly’s Compass Software, and integrating Butterfly iQ3 across their institution to deliver state-of-the-art early diagnosis and unlock these strong clinical and financial results.”
To read the full case study visit: https://butterflynetwork.com/case-studies-urmc. For more information on Butterfly Network, visit www.butterflynetwork.com.
For more information on the University of Rochester Medical Center, visit https://www.urmc.rochester.edu.
About Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011, Butterfly Network is a digital health company with a mission to democratize medical imaging by making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Butterfly created the world's first handheld single-probe, whole-body ultrasound system using semiconductor technology, Butterfly iQ. The company has continued to innovate, leveraging the benefits of Moore’s Law, to launch its second-generation Butterfly iQ+ in 2020, and third generation iQ3 in 2024 – each with increased processing power and performance enhancements. The disruptive technology has been recognized by TIME’s Best Inventions, Fast Company’s World Changing Ideas, CNBC Disruptor 50, and MedTech Breakthrough Awards, among other accolades. With its proprietary Ultrasound-on-Chip™ technology, intelligent software, and educational offerings, Butterfly is paving the way to mass adoption of ultrasound for earlier detection and remote management of health conditions around the world. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: www.butterflynetwork.com/choose-your-country.
